The health care industry is watching closely as President Donald Trump prepares to hold his speech on U.S. drug pricing today.
According to a Bloomberg article, Cowen analysts believe the speech will turn out “relatively benign, with more drastic proposals coming at a later date or not at all.”
Near-term market impact remains uncertain on Wall Street, according to the report.
Health and Human Services Secretary Alex Azar said last week the president’s plan will go “much further” than the 2019 budget proposal on high list prices and out-of-pocket spending.
To read more about what to expect from Trump’s speech today, click here.
